{
	"AGNG_news": [
		{
			"stock": "AZN",
			"news_titles": [
				"CanSino Biologics on AstraZeneca Deal, Earnings",
				"Medicare price negotiation list: What it means for pharma companies",
				"Expensive Drugs Targeted for First U.S. Price Negotiations",
				"Analyst Report: AstraZeneca PLC",
				"The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca",
				"Biden Administration targets drugs from J&J, Merck for controversial Medicare price negotiations",
				"Oncology Market's Huge Potential Puts These Stocks in Focus",
				"Ken Fisher’s Top 15 Healthcare Stock Picks"
			]
		},
		{
			"stock": "JNJ",
			"news_titles": [
				"Analyst Report: Johnson & Johnson",
				"Medicare's drug pricing list didn't impact company stocks — here's why",
				"Johnson & Johnson Forecasts Double-Digit Earnings Growth After Kenvue Spin-Off",
				"Merck's (MRK) Keytruda Receives EU Nod in Gastric Cancer",
				"Medicare price negotiation list: What it means for pharma companies",
				"J&J, India's Lupin cut prices for tuberculosis drug in lower-income countries",
				"Johnson & Johnson Revises Guidance After Kenvue Spinout. There’s Good News on the Dividend.",
				"Midday movers: HP Inc., Nvidia, Coinbase and more"
			]
		},
		{
			"stock": "BMY",
			"news_titles": [
				"Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know",
				"Multiple Reasons to Keep Off This Pharma Stock",
				"Medicare's drug pricing list didn't impact company stocks — here's why",
				"Medicare price negotiation list: What it means for pharma companies",
				"Apellis Pharmaceuticals, Inc. (APLS) Up 67.8% Since Last Earnings Report: Can It Continue?",
				"What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks?",
				"Eli Lilly and Other Pharma Stocks Are Ignoring Medicare’s 10 Drug List",
				"Analyst Report: Bristol-Myers Squibb Company"
			]
		},
		{
			"stock": "ABBV",
			"news_titles": [
				"Top Dividend Stocks: In Biotech Space, AbbVie Entices With 4% Yield",
				"Medicare's drug pricing list didn't impact company stocks — here's why",
				"Medicare price negotiation list: What it means for pharma companies",
				"Journal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BOTOX® Cosmetic)",
				"Expensive Drugs Targeted for First U.S. Price Negotiations",
				"The Unexpected Bad News For Novo's Ozempic In Biden's Drug Negotiations List",
				"AbbVie's Quant Upgrade Gets My Attention. Bullish Charts Keep It",
				"Analyst Report: AbbVie Inc."
			]
		},
		{
			"stock": "BSX",
			"news_titles": [
				"If You Invested $1000 in Boston Scientific a Decade Ago, This is How Much It'd Be Worth Now",
				"PBH vs. BSX: Which Stock Should Value Investors Buy Now?",
				"Company News for Aug 29, 2023",
				"S&P 500 Gains and Losses Today: Index Adds to Last Week's Advance After Powell's Comments",
				"Boston Scientific Surges As It Looks To Enter A Market Worth Nearly $8 Billion",
				"Boston Scientific Leads the S&P 500",
				"3M, Boston Scientific rise; Abcam, NovoCure fall, Monday, 8/28/2023",
				"Boston Scientific Reports Positive Results from Atrial Fibrillation Device"
			]
		}
	]
}